Loading
Stage Iv Lung Cancer AJCC V8 / Osimertinib / Computed Tomography · Phase 2 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for a biologically guided radiation therapy and SBRT strategy combined with osimertinib in oligoprogressive EGFR-positive NSCLC. The trial is currently suspended and no results are posted in this registry record. No efficacy or safety data are available to inform clinical practice.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8; age from 18 Years. Intervention: Treatment (BgRT/SBRT). n = 32. 2 sites: United States.
This is a Phase 2 trial registration for a biologically guided radiation therapy and SBRT strategy combined with osimertinib in oligoprogressive EGFR-positive NSCLC. The trial is currently suspended and no results are posted in this registry record. No efficacy or safety data are available to inform clinical practice.
No safety, efficacy, or comparative data provided.
This registration provides no clinical data; results are needed before any practice recommendations can be made. Clinicians should monitor for future publication of this trial's outcomes.
This is a suspended Phase 2 trial registration with no results reported; it describes a planned intervention but carries no outcome data to evaluate efficacy or safety.
As stated by the source record.
Quoted from the source exactly as published.
This registration provides no clinical data; results are needed before any practice recommendations can be made. Clinicians should monitor for future publication of this trial's outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06014827). This is a study registration, not published results. Lead sponsor: City of Hope Medical Center. Recruitment status: SUSPENDED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 32 participants (ESTIMATED). Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8. Interventions: PROCEDURE: Biospecimen Collection; PROCEDURE: Computed Tomography; DRUG: Osimertinib; PROCEDURE: Positron Emission Tomography; RADIATION: Stereotactic Body Radiation Therapy; OTHER: Survey Administration. Primary outcome measures: Percent of patients on planned protocol treatment , At 6 months. Brief summary: This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has spread from where it first started (primary site) to a limited number of anatomic sites (oligoprogressive). BgRT is radiation that uses specialized imaging to during treatment to target the active tumor and direct radiation to tumors in order to kill and shrink tumor cells. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving BgRT with SBRT and osimertinib may kill more tumor cells in patients with oligoprogressive EGFR positive non-small cell lung carcinoma.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.